Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 randomized, blinded, placebo-controlled multi-center trial of emetine in high-risk, symptomatic adult patients with confirmed COVID-19 infection not requiring hospitalization

Next Previous
Search
Trial Profile

Phase 2/3 randomized, blinded, placebo-controlled multi-center trial of emetine in high-risk, symptomatic adult patients with confirmed COVID-19 infection not requiring hospitalization

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 19 Aug 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emetine (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 13 Aug 2020 According to an Acer therapeutics media release, the company is planning to submit IND clearance in the first half of 2021 followed by the initiation of this study.
    • 18 May 2020 New trial record
    • 11 May 2020 According to an Acer therapeutics media release, has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS), one of the National Institutes of Health (NIH) for the development develop of emetine hydrochloride as a potential treatment for patients with COVID-19

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top